Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338651 | 0.72 | HNF4A (0.36) | HNF4A | |
| SCHEMBL6340481 | 0.71 | PTGS1 (0.32) | — | |
| SCHEMBL15397113 | 0.71 | HNF4A (0.35) | HNF4A | |
| SCHEMBL7133427 | 0.70 | PTGS1 (0.44) | — | |
| SCHEMBL6341491 | 0.70 | CA12 (0.34) | HNF4A | |
| SCHEMBL8731890 | 0.69 | HTR1A (0.36) | HNF4A | |
| SCHEMBL12465678 | 0.69 | SSTR5 (0.33) | HNF4A | |
| SCHEMBL6348348 | 0.69 | HNF4A (0.32) | HNF4A | |
| SCHEMBL24184513 | 0.68 | KDM4E (0.42) | HNF4A | |
| SCHEMBL21828706 | 0.68 | HNF4A (0.44) | HNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849658-B2 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-02-01 | — | — | US | disclosed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | disclosed |
| EP-0977749-B1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-03-13 | — | — | EP | disclosed |
| US-6346546-B1 | COMPOUNDS HAVING MARKED ACTIVITY IN FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION; TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | AR, SRR, MC3R | HNF4A 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.